The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2019 | Dr Camidge on novel NSCLC agents: we want to see the duration of benefit
Ross Camidge
• 28 Sep 2019
Ross Camidge, MD, PhD, University of Colorado, Denver, CO, gives his thoughts on the new data in lung cancer – highlighting the need to see a duration of benefit. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
